2013 Documentation Pharmaceutical Companies 
European Pharmaceutical Review
JULY 5, 2023
Having been originally published in 2007, then revised in 2013, this latest 2023 edition addresses evolving standards and container types. According the PDA, the standardised quality criteria in TR 43 are intended as a guidance overview for container manufacturers and for incoming container acceptance inspection at pharmaceutical companies.
pharmaphorum
AUGUST 23, 2021
The possibility of data being shared with third-parties including academic researchers and pharmaceutical companies raised concerns about whether the public is aware that they stand to lose control of private information on their physical, mental and sexual health. Now that’s been set back indefinitely. survey conducted in July.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
European Pharmaceutical Review
SEPTEMBER 22, 2022
Dr Maier has over 25 years of experience in drug development and commercialisation at pharmaceutical companies in Europe, Canada, the United States and Asia. 2013 Oct; 48(10): 943–953. Published online 2013 Jul 2. Mayer-Hamblett N, Rosenfeld M, Treggiari MM et al. Pediatr Pulmonol. doi: 1002/ppul.22693. Thompson, LA.
European Pharmaceutical Review
FEBRUARY 1, 2024
In this Q&A, he explores the trends and challenges within the cardiovascular treatment space, as well as clinical development of the company’s lead candidate obicetrapib, a cholesterol ester transfer protein (CETP) inhibitor for lowering low-density lipoprotein-cholesterol (LDL-C) and ultimately reducing cardiovascular risk.
Pharmaceutical Technology
NOVEMBER 4, 2022
At the time of its publication, the document prioritised the finalisation of Brexit above all else. For the life sciences and pharmaceutical sector, the Conservative government promised £34 billion ($38.98 In a more recent report, the ABPI found that the number of Phase III industry trials fell by 48% between 2017 and 2021.
ISPE
MAY 9, 2023
In an era when the world is accelerating the development of drugs and targeted medicines using innovative technologies, pharmaceutical companies still face registration hurdles for well-characterized molecules because of redundant or additional local regulatory requirements.
The People's Pharmacy
MAY 8, 2023
There have been problems with records in the past: deceit, falsification of documents and even outright fraud. Since the start of 2013, pharmaceutical companies based in the U.S. But a whistleblower at the company reported that some of the scientists there were falsifying data. Carcinogens in Blood Pressure Meds?
Expert insights. Personalized for you.
96 
Let's personalize your content